// 1
INSPIRING THE WORLD
TO MOVE WELL
INVESTOR UPDATE
JULY 2017
For
per
sona
l use
onl
y
// 2
This presentation does not constitute investment, legal, taxation or other advice and the
presentation does not take into account your investment objectives, financial situation or particular
needs. You are responsible for forming your own opinions and conclusions on such matters and
should make your own independent assessment of the information presented. No responsibility is
accepted by dorsaVi or any of its respective officers, employees, agents, advisers or associates
for any of the information or for any action taken by you on the basis of that information. Any and
all use of the information is at your own risk.
Certain information may relate to protected intellectual property rights owned by dorsaVi Ltd (the
"Company”). Except as required by law, no representation or warranty, express or implied, is
made as to the accuracy, completeness or correctness of the information, opinions and
conclusions, or as to the reasonableness of any assumption contained in this presentation. By
receiving this information and to the extent permitted by law, you release dorsaVi and its
respective officers, employees, agents, advisers and associates from any liability (including,
without limitation, indirect or consequential loss or damage, or loss or damage arising by
negligence) arising as a result of the reliance by you or any other person on anything contained in
or omitted from this document or presentation.
DISCLAIMERF
or p
erso
nal u
se o
nly
// 3
• Investment highlights
• About dorsaVi
• Operational update
• ViSafe overview
• ViMove overview
• ViPerform overview
• Outlook
AGENDA
INSPIRING THE WORLD TO MOVE WELL™
REVOLUTIONARY
WEARABLE SENSOR
TECHNOLOGY
For
per
sona
l use
onl
y
// 4INVESTMENT HIGHLIGHTS
• First mover advantage, leader with medical grade wearable technology – FDA, CE Mark, TGA approved
• Three attractive markets – Occupational Health & Safety, Clinical, and Elite Sports
• Across three geographic markets – US, UK and Australia
• FY 17 revenue up 15% on FY16 FY (21% in constant currency)
• US FY17 161% up on US FY16 revenue ($450k to $1.18K AUD)
• US reimbursement supporting US roll out
• Annuity revenue building in the US clinical and OHS market
• Large operational leverage:
• Costs stable
• US agency model (7 agents in Americas)
• Annuity revenues emerging from the OHS market through myViSafe product:
• Successful launch in Australia, UK and US markets
• Mini sensors and App used in the OHS market that create annuity revenue
• Launch of smaller and easier to use mini sensors ViMove2:
• Driving more rapid and online sales growth in Australian market
• FDA clearance for ViMove2 for US launch Q3/Q4 2018
• Lower COGS, attractive margins and payback
For
per
sona
l use
onl
y
// 5
About dorsaVi
For
per
sona
l use
onl
y
// 6BOARD AND SENIOR MANAGEMENT
Non Executive Director
Michael Panaccio
Chairman
Herb Elliott
Non Executive Director
Greg Tweedly
Non Executive Director
Ash Attia
Director & CEO
Andrew Ronchi
CFO
Damian Connellan CIO
Meagan Blackburn
CPO
Muhammad Umer
CMO
Megan Connell Head of Sales and
Operations Europe
Zoë Whyatt
Head of Sales and
Operations Australia
Matt May
Head of Sales and
Operations US
Mark Heaysman
For
per
sona
l use
onl
y
// 7OUR BUSINESS: SOLID FOUNDATION FOR GROWTH
• Three key business divisions with diversified revenue streams
• Occupational health and safety
• Clinical
• Elite sports
• Market leader with first mover advantage
• Patent protected technology
• Significant barriers to entry and limited competition
• FDA approval
• TGA approval
• CE Mark
• Currently focused on three key geographies
• United States
• United Kingdom
• AustraliaFor
per
sona
l use
onl
y
// 8STRONG PRODUCT PORTFOLIO
• Patent protected movement algorithms
on medical-grade sensor technology
• Function-specific applications which
deliver meaningful movement data to
our target markets
• OHS solution to determine, measure and mitigate high risk activities
• Significant appetite for innovative manual handling solutions
• Executive and board-level focus on reducing injuries and
associated costs
• Budget readily available
• Growing portfolio of products to capitalise on opportunities
• Clinical solution with turnkey applications for low back, running and
a range of other functional measures
• Early adopter advocates in key geographic markets of
Australia, US and UK
• Distribution partners in US and UK
• Elite sporting solution used in off-field
environments to measure stress and prevent injury
• Widespread use across many codes – AFL,
NRL, NBA, NFL, NHL, EPL
• Sporting business growing via word of
mouth
For
per
sona
l use
onl
y
// 9
?
For
per
sona
l use
onl
y
// 10
Operational Update
For
per
sona
l use
onl
y
// 11
FINANCIAL OVERVIEW
dorsaVi Ltd (ASX : DVL)
Share price $0.35
Shares on issue 167,305,859
Market capitalisation $58.6M
2013 2014 2015 2016 2017
Revenue 398,607 529,380 1,358,218 3,019,928 3,466,000*
EBITDA (2,148,749) (3,852,593) (8,684,709) (5,915,567) N/A
Loss from
continuing
operations
(1,659,235) (3,562,024) (8,036,161) (5,237,102) N/A
Cash position $13.94M $5.74M $6.03M $8.61M
*unaudited results
For
per
sona
l use
onl
y
// 12
GROWTH IN MAJOR MARKETS
UKAU US
For
per
sona
l use
onl
y
// 13
EXECUTION ACROSS THE PRODUCT LINES
ViSafe (OHS)• ViSafe continues to grow across all three geographic markets
• Launched myViSafe - self managed solution within ViSafe portfolio creating annuity revenue
• Scalable across small to large corporations
ViMove (Clinical)• Launch of ViMove2 – App-based mini sensors, new price point, reduced COGS
• US: Select Medical (2,000 clinical sites) Initial pilot 20 (currently at 40 sites)
• Clinical trial shows ViMove reduces pain by 45% & improves function by 73%
• Health economic paper released which shows ViMove delivers both improved clinical
outcomes and reduced economic impact
ViPerform (Sport)• NBA Teams (LA Lakers), NFL Teams (New England Patriots)
• NHL (Philadelphia Flyers)
• Initial US College sites (Ohio State & Marquette)
• Athletic Movement Index most popular module in USA
For
per
sona
l use
onl
y
// 14
REDUCING COSTS & INJURY
IMPROVING PRODUCTIVITY
BUILDING SAFETY CULTURE
For
per
sona
l use
onl
y
// 15F
or p
erso
nal u
se o
nly
// 16
SCALABLE REVENUE MODEL
ASSESS SOLVE IMPLEMENT
AUDIT +
MONITOR +
TRAIN +
COMPARE +
SOLVE PROBLEMS =
TRANSFORM +
EMBED +
COMMUNICATE +
DELIVER +
AFFECT CHANGE =
SCOPE +
COLLECT +
COMPARE +
UNDERSTAND =
$40,000 $100,000 $300,000
For
per
sona
l use
onl
y
// 17
myViSafe BUSINESS MODEL
• Self managed solution for organisations to
monitor employee movement
• Key applications
• Manual handling training
• Compliance testing
• Issue identification
• Accessible to a very large market – for
organisations with more than 100 employees
• High volume solution, low touch support
• Attractive price point – starting at $9,500
• Software licence $10k - $70K p.a.
• Scalable annuity revenue from small to large
corporates
http://dmdatabases.com/databases/business-mailing-lists/how-many-businesses
No. of Employees No. of Businesses
5,000+ 3,518
1,000 – 4,999 11,338
100 - 999 214,948
Number of US businesses appropriate for myViSafe
For
per
sona
l use
onl
y
// 18
AGENT MODEL BUILDING FOR RAPID REVENUE GROWTH
Scalable model:
• Direct sales representatives in key
markets
• Sales partnerships with agents
• 7 agents signed up across US
• Centralised analysis
For
per
sona
l use
onl
y
// 19
FDA CLEARED, CE MARK, TGA
SUPPORTED BY CLINICAL
TRIAL DATA
For
per
sona
l use
onl
y
// 20
THE INVESTMENT CASE FOR ViMove2
Benefits of ViMove2 for dorsaVi and Investors
• $5M development over 2 years with market feedback from 3 geographies
• Significantly reduced COGS allowing scalable model
• Faster, easier to use product to drive utilisation
• Reduces training and face to face time from 4 hours to 10 minutes
• Product designed to enhance patient experience
• Allows easier entry into new geographies
• Business model $3k up front and $3k p.a.
Geo No. of Physios
Australia 24,000
UK 48,000
USA 284,000
Number of Physiotherapists
For
per
sona
l use
onl
y
// 21
LOW BACK KNEERUN
For
per
sona
l use
onl
y
// 22
ViMove2 RUN
ViMove2 Run enables clinicians to
quickly understand how a runner is
moving – gait lab in your own clinic.
Tests
• Distance
• Speed
• Style
What is measured
• Leg Symmetry
• Average Ground Reaction Force
• Average Initial Peak Acceleration
• Average Ground Contact Time
• Average Steps Per Minute
• Total Distance
• Average Speed
• Time
• Access reports
• View assessment data
• Follow prescribed
exercise programs
For
per
sona
l use
onl
y
// 23
ViMove2 LOW BACK
ViMove2 Low Back quickly gains a clearer picture by assessing
lumbar spine movement in real-time, automatically prescribing
exercises that are appropriate for patients based on the
assessment data.
Tests
• Lumbar Lordosis
• Flexion
• Extension
• Lateral Flexion
• Standing Pelvic Tilt
• Sitting Posture
• Sitting Pelvic Tilt
• Sitting Rotation
What is measured
• Range of Movement
• Postural Angles
• Quality of Movement
For
per
sona
l use
onl
y
// 24
ViMove2 KNEE
Historically it has been difficult to visualise quality of knee movement, especially
in dynamic movements such as hopping and landing. With ViMove2 Knee,
clinicians can quickly assess the stresses and strains placed on a patient’s
knees in real-time.
Tests
• Double Leg Squat
• Single Leg Squat
• Hop
What is measured
• Tibial Inclination
• Valgus and Varus Range of Movement
• Valgus and Varus Speed
• Flight Time
For
per
sona
l use
onl
y
// 25
AUSTRALIAN CLINICAL MARKET
24,000 Physios in Australia
• Conservative cottage industry
• Not commercial minded
• Critical thinkers
• Very hands on model (1:1)
• Lean business model (low margins)
• Tech averse
• 4 years to sign on >100 sites
• 80% retention rate
For
per
sona
l use
onl
y
// 26
284,000 Physical Therapists in the USA
• Franchise model with acquisitions occurring
• Commercially minded
• Less hands on
• Treat multiple patients at a time (1:4)
• More tech savvy
• Outreach business model
• Schools and colleges screening large numbers
• 2 years to sign on 160 sites
• 100% retention rate
CLINICAL SCALE IN THE US MARKETdorsaVi clinical sites and number of PT’s by state
Bureau of Labour Statistics, OES May 2016 Data (https://www.bls.gov/oes/tables.htm)
For
per
sona
l use
onl
y
// 27
CLINICAL TRIAL SHOWS TREATMENT AND COST BENEFIT
• 8 week program
• 45% pain
• 73% function
• Lasting benefit at 12 months
• Exceptional health economic
outcomes
RANDOMISED
CONTROLLED TRIAL
Peer reviewed clinical trial showing dramatic improvement
for low back pain
“This evaluation has identified that motion-sensor
biofeedback intervention using ViMove system
was both more effective and less costly overall
than the control from the societal perspective.
Rarely are health care interventions found to
be both more effective and less costly overall”
Professor Terry Haines (Monash University)
Clinical Treatment Benefit Economic/Cost Benefit
For
per
sona
l use
onl
y
// 28
BRANDING AND
CREDIBILITY
For
per
sona
l use
onl
y
// 29
ELITE SPORTS MARKET: WORKING WITH INNOVATORS
• Working with thought leaders
• Growth through word of mouth
For
per
sona
l use
onl
y
// 30
APPLICATIONS IN THE RETAIL & CONSUMER WORLD
• Retail groups need point of differentiation to attract shoppers
• Runners stores, pharmacies, consumer retailers
• Engaging tech and immediate feedback works
• Strong evidence for increase in sales from use of customers own data
For
per
sona
l use
onl
y
// 31
OutlookF
or p
erso
nal u
se o
nly
// 32
WORLD LEADERS USING dorsaVi TECHNOLOGY
MEDICAL DEVICES
• Large companies with a special interest in movement
• Track and monitor patient both pre & post surgery
• Want to provide better outcomes for their product
PHARMACEUTICALS
• Independent evidence on how their drugs are performing
• Are people moving better?
• Do the patients have less muscle spasm?
HOSPITALS
• Aiming to reduce admissions
• Monitor patients at home and engage them in recovery
• Conduct commercial pilots using cutting edge tech
• Publish trial results with KOLs as authors
UNIVERSITIES
• Develop better treatment protocols
• Conduct sophisticated clinical trials using new
tech outcomes
• Educate the next generation of clinicians and ergonomists
For
per
sona
l use
onl
y
// 33
UPCOMING NEWSFLOW
• Annuity revenue growing with myViSafe in major geos
• Traction of ViMove2 in the Australian clinical market
• New OHS contracts with major corporates (US, UK & Australia)
• Continue to grow US OHS sales agents
• Custom applications with market leaders
For
per
sona
l use
onl
y
// 34
dorsaVi™
Andrew Ronchi
PhD (Eng), B.App.Sci (Physio)
Chief Executive Officer
Level 1, 120 Jolimont Road,
East Melbourne, Victoria 3002
Office: +61 9652 2192 | Mobile: +61 417 882 267
[email protected] | dorsaVi.com
For
per
sona
l use
onl
y